Coho Partners Ltd. Has $7.15 Million Position in Kenvue Inc. (NYSE:KVUE)

Coho Partners Ltd. lessened its stake in shares of Kenvue Inc. (NYSE:KVUE) by 6.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 335,044 shares of the company’s stock after selling 23,800 shares during the period. Coho Partners Ltd.’s holdings in Kenvue were worth $7,153,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Leo Wealth LLC raised its holdings in Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares in the last quarter. Alerus Financial NA raised its holdings in Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC raised its holdings in Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after acquiring an additional 500 shares in the last quarter. Principle Wealth Partners LLC raised its stake in Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock valued at $303,000 after buying an additional 500 shares during the period. Finally, Wolff Wiese Magana LLC raised its stake in Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.00.

Kenvue Stock Performance

KVUE stock opened at $21.47 on Friday. The stock has a 50-day moving average price of $21.37 and a 200-day moving average price of $22.03. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $41.15 billion, a PE ratio of 40.50, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.82%. Kenvue’s dividend payout ratio is presently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.